LamKap Bio alpha

LamKap Bio alpha is a Swiss clinical-stage biotechnology company focused on the development of monoclonal antibodies for the treatment of chronic inflammatory diseases. The company's lead program is LKB-001 (formerly NI-0101), a first-in-class monoclonal antibody that targets Toll-like receptor 4 (TLR4), an asset acquired from Novimmune. LamKap Bio alpha employs a precision medicine strategy, aiming to treat specific subpopulations of rheumatoid arthritis patients who exhibit a TLR4-driven disease signature. The company was founded by a team of experienced industry executives from Roche and Novimmune and operates as part of the broader LamKap Bio group of asset-centric entities.